Shamburg News · 8-K filed Nov 17, 2026, 9:42 AM EST
Pacira BioSciences Completes Merger with Viatris; Shares Converted to $36.50 Cash
PCRX · Pacira BioSciences, Inc.
- Acquisition
- Material agreement
- Financing
- Delisting
- Leadership change
- Shareholder vote
- Reg FD disclosure
- Other event
- Materiality: high
On November 17, 2026, Pacira BioSciences completed its merger with Viatris following a tender offer that was accepted at $36.50 per share in cash. The Company's common stock is to be delisted from Nasdaq, and the Company repaid $96,392.50 in full under its Credit Agreement and terminated it. Holders of the 2.125% Convertible Senior Notes due 2029 may convert at cash rates including Additional Shares through January 8, 2027, under a First Supplemental Indenture.
Source: SEC EDGAR, Form 8-K, Items 1.01, 1.02, 2.01, 2.04, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01, accession 0001140361-26-044354.
Written from the filing by Shamburg Markets. Figures are as reported by the company.